Jci_page_head_homepage_01 Jci_page_head_homepage_02
Kristine A. Kuhn, Liudmila Kulik, Beren Tomooka, Kristin J. Braschler, William P. Arend, William H. Robinson, V. Michael Holers
Published in Volume 116, Issue 4
J Clin Invest. 2006; 116(4):961–973 doi:10.1172/JCI25422
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 1
Anti-CCP antibodies appear prior to visible arthritis and in parallel with the appearance of anti-collagen antibodies.

(A) Six- to 8-week-old DBA/1J mice were untreated or were immunized at day 0 with CII in CFA or CFA alone and then received booster immunizations 21 days later (black arrows). Sera were collected every 7 days and analyzed for antibody levels. Mice were also observed and scored for development of clinical arthritis. Visible signs of arthritis were measured by adding the number of swollen digits on all 4 paws of each mouse. (B) IgG and (D) isotype-specific antibodies against CII were measured by ELISA as described in Methods. (C) IgG and (E) isotype-specific anti-CCP antibodies were measured by ELISA as described in Methods. IgG3 anti-CCP antibodies were below the limits of detection by ELISA and thus are not shown. The data for each mouse within a group are averaged for that group and represented α SEM. For each group, n = 12. Statistical significance was determined using a 1-way ANOVA. *P < 0.05; **P < 0.01; ***P < 0.001 in CIA mice compared with CFA-immunized and unimmunized mice. (F) Sera from Rag1–/– mice (n = 5) were tested and compared with unimmunized DBA/1J (normal mouse serum (NMS); n = 7 for IgM and n = 23 for IgG). Statistical significance was determined using an unpaired 2-tailed Student’s t test. #P = 0.0004 for IgM anti-CCP antibodies in NMS rsus Rag1–/– mice.